Ovarian reserve and subsequent assisted reproduction outcomes after methotrexate therapy for ectopic pregnancy or pregnancy of unknown location
- PMID: 24269042
- PMCID: PMC3946660
- DOI: 10.1016/j.fertnstert.2013.10.027
Ovarian reserve and subsequent assisted reproduction outcomes after methotrexate therapy for ectopic pregnancy or pregnancy of unknown location
Abstract
Objective: To assess ovarian reserve after methotrexate treatment for ectopic pregnancy or pregnancy of unknown location after assisted reproductive technology (ART).
Design: Retrospective cohort study.
Setting: Large ART practice.
Patient(s): Women receiving methotrexate or surgery after ART.
Intervention(s): None.
Main outcome measure(s): Follicle-stimulating hormone (FSH), antral follicle count (AFC), and oocyte yield compared between women treated with methotrexate or surgery, with secondary outcomes of clinical pregnancy and live birth.
Result(s): There were 153 patients in the methotrexate group and 36 patients in the surgery group. Neither group demonstrated differences in ovarian reserve or oocyte yield in a comparison of the before and after treatment values. The change in ovarian reserve and oocyte yield after treatment were similar between the two groups. The number of doses of methotrexate was not correlated with changes in ovarian reserve, indicating no dose-dependent effect. Time between treatment and repeat ART was not correlated with outcomes. Live birth in subsequent cycles was similar in the two groups.
Conclusion(s): Ovarian reserve and subsequent ART cycle outcomes were reassuring after methotrexate or surgical management of ectopic pregnancy. No adverse impact of methotrexate was detected in this large fertility cohort as has been previously described elsewhere.
Keywords: ART; ectopic; methotrexate; ovarian stimulation; pregnancy of unknown location; salpingectomy.
Published by Elsevier Inc.
Figures
Comment in
-
Methotrexate treatment of ectopic pregnancies does not affect ovarian reserve in in vitro fertilization patients.Fertil Steril. 2014 Feb;101(2):337-8. doi: 10.1016/j.fertnstert.2013.11.010. Epub 2013 Dec 17. Fertil Steril. 2014. PMID: 24355052 No abstract available.
-
Methotrexate for assisted reproductive technology (ART) ectopic pregnancy.Fertil Steril. 2014 Feb;101(2):e11. doi: 10.1016/j.fertnstert.2013.11.124. Fertil Steril. 2014. PMID: 24485505 Free PMC article. No abstract available.
References
-
- Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer. 1978;41:36–51. - PubMed
-
- Barnhart K, Hummel AC, Sammel MD, Menon S, Jain J, Chakhtoura N. Use of “2-dose” regimen of methotrexate to treat ectopic pregnancy. Fertil Steril. 2007;87:250–6. - PubMed
-
- McLaren JF, Burney RO, Milki AA, Westphal LM, Dahan MH, Lathi RB. Effect of methotrexate exposure on subsequent fertility in women undergoing controlled ovarian stimulation. Fertil Steril. 2009;92:515–9. - PubMed
-
- Orvieto R, Kruchkovich J, Zohav E, Rabinson J, Anteby EY, Meltcer S. Does methotrexate treatment for ectopic pregnancy influence the patient’s performance during a subsequent in vitro fertilization/embryo transfer cycle? Fertil Steril. 2007;88:1685–6. - PubMed
-
- Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer. 2007;110:2222–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
